Transforming Growth Factor Beta Receptor Type II (TGFBR2)

Transforming growth factor beta receptor type II (TGFBR2) is a transmembrane serine/threonine protein kinase crucial for the TGF-β signaling pathway, involved in cell proliferation, differentiation, motility, and apoptosis. Encoded by the TGFBR2 gene, it functions as a tumor suppressor gene. The protein has extracellular, transmembrane, and intracellular kinase domains. Ligand binding activates TGFBR2, leading to heterodimer formation with TGFBR1, phosphorylation of SMAD proteins (SMAD2/SMAD3), complex formation with SMAD4, and nuclear translocation to regulate gene transcription. TGFBR2 exhibits dual roles: tumor suppression in early stages by inhibiting proliferation and promoting apoptosis, but promoting tumor progression, metastasis, therapy resistance, and immunosuppression in advanced cancers. Mutations in TGFBR2 are associated with various tumors and cause Loeys-Dietz syndrome type II, a connective tissue disorder. TGFBR2 is a therapeutic target, with approaches including bispecific antibodies, dominant negative constructs, and small molecule inhibitors of the pathway. The dual, context-dependent role of TGF-β signaling poses significant challenges for therapeutic development.

Targeting TGFBR2 aims to modulate the TGF-β signaling pathway, typically by inhibiting its activity, to influence cellular processes like proliferation, apoptosis, and immune response, particularly in the context of cancer progression.